Foundation Medicine Inc (NASDAQ: FMI) and Tekmira Pharmaceuticals Corp (TSX: TKM), lead the top small cap stock gainers for various sectors on both sides of the border, including one that saw its share price surge 95%.
Top U.S. Gainer
|
Company Name |
Exchange |
Ticker |
Market Cap |
Last Price |
Last Volume |
Price Return |
Price Return |
52-Week High |
52-Week Low |
|
Foundation Medicine Inc |
NASDAQ |
FMI |
1,323.7 |
46.74 |
9,010,460 |
95.3% |
108.1% |
54.28 |
18.25 |
Foundation Medicine Inc (NASDAQ: FMI), engaged in the business of providing methods and algorithms for analyzing tumor tissue samples across all types of cancer, as well as information aggregation and concise reporting capabilities, was the top performer in the U.S. healthcare sector after skyrocketing 95.3% and closed at $46.74 Monday, while recording significant trading volumes of 9.0 million shares. FMI broke its key technical resistance levels of 50-Day and 200-Day DMAs at $24.08 and $24.24 respectively. The share price rose due to the recent announcement made by the company about its strategic collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) in the field of Molecular Information in Oncology. Roche will tender for approximately 15.6 million Foundation Medicine shares at $50 per share with an aggregate tender value of approximately $780 million. During the past 5-trading sessions, FMI gained 108.1% with daily average trading volumes of 2.0 million shares, while the stock accumulated 117.1% gain during the past one month with daily average trading volumes of 594,211 shares. The stock is up 110.3% year-to-date.
1-Year Price Chart
Top Canadian Gainer
|
Company Name |
Exchange |
Ticker |
Market Cap |
Last Price |
Last Volume |
Price Return |
Price Return |
52-Week High |
52-Week Low |
|
Tekmira Pharmaceuticals |
TSX |
TKM |
657.6 |
29.38 |
812,903 |
56.0% |
66.1% |
34.66 |
9.55 |
Tekmira Pharmaceuticals Corp (TSX: TKM),a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical and biotechnology partners, was the top sector gainer after skyrocketing 56.0% and closed at C$29.38 Monday, while recording significant trading volumes of 812,903 shares. The share price rose due to the company’s recent announcement of merger agreement with OnCore Biopharma to create a new leading global HBV (Hepatitis B Virus) company, focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches. During the past 5-trading sessions, TKM gained 66.1% with daily average trading volumes of 194,409 shares, while the stock accumulated 78.3% gain during the past one month with daily average trading volumes of 78,615 shares. The stock is up 65.3% year-to-date.
1-Year Price Chart
